AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26230902 — intervention group
Group type: EXPERIMENTAL
Intervention: BF (breast-fed)
Number of subjects: 157
Study 23980535 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week group psychoeducational programme (n = 36)
Number of subjects: 71
Study 23980535 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 35)
Number of subjects: 71
Study 22378725 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsinoids (9 mg)
Number of subjects: 18
Study 22378725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 20125159 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD-MTX)
Number of subjects: 55
Study 20125159 — intervention group
Group type: COMPARATOR
Intervention: High-dose methotrexate (HD-MTX) and high-dose cytarabine (HD-AraC)
Number of subjects: 55
Study 17347177 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (7.5 mg/kg, intramuscular, once daily)
Number of subjects: 34
Study 15963201 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiocolchicoside (TCC)
Number of subjects: 0
Study 15963201 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine (TZ)
Number of subjects: 0
Study 15963201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14612224 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 241
Study 14612224 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 241
Study 14612224 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine and interpersonal psychotherapy
Number of subjects: 241
Study 14612224 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious group
Number of subjects: 241
Study 14612224 — intervention group
Group type: COMPARATOR
Intervention: Nonanxious group
Number of subjects: 241
Study 10584136 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg, day 1 to 5 and 29 to 33) during concurrent radio-chemotherapy with carboplatin (70 mg/m2, day 1 to 5 and 29 to 33)
Number of subjects: 28
Study 10584136 — intervention group
Group type: COMPARATOR
Intervention: Control group (no amifostine)
Number of subjects: 28
Study 10584136 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 28
Study 8969478 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlational method to estimate listener's weighting function for speech
Number of subjects: 3
Study 1988577 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC 50 (5FU 500 mg/m2, cyclophosphamide 500 mg/m2, epirubicin 50 mg/m2)
Number of subjects: 412
Study 1988577 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC 75 (5FU 500 mg/m2, cyclophosphamide 500 mg/m2, epirubicin 75 mg/m2)
Number of subjects: 412
Study 1988577 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin alone (75 mg/m2)
Number of subjects: 412
Study 1988577 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC 75
Number of subjects: 412
Study 1988577 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC 50
Number of subjects: 412
Study 1988577 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin alone
Number of subjects: 412
Study 7081136 — intervention group
Group type: COMPARATOR
Intervention: DA (dibromodulcitol + Adriamycin)
Number of subjects: 135
Study 7081136 — intervention group
Group type: EXPERIMENTAL
Intervention: DAT (dibromodulcitol + Adriamycin + tamoxifen)
Number of subjects: 135
Study 7081136 — intervention group
Group type: EXPERIMENTAL
Intervention: DATN (dibromodulcitol + Adriamycin + tamoxifen for patients < 50 years)
Number of subjects: 135
Study 30909079 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally informed brief motivational intervention
Number of subjects: 0
Study 30909079 — intervention group
Group type: COMPARATOR
Intervention: Standard brief intervention for alcohol use
Number of subjects: 0
Study 30074491 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration-high cutoff
Number of subjects: 76
Study 30074491 — intervention group
Group type: COMPARATOR
Intervention: Continuous venovenous hemofiltration-standard
Number of subjects: 76
Study 26717887 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone/Vincristine (Dx/VCR) trial
Number of subjects: 0
Study 26717887 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP) trial
Number of subjects: 0
Study 26717887 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase (ASP) trial
Number of subjects: 0
Study 24515544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystoscopic onabotulinum toxin A injection and oral placebo medication
Number of subjects: 155
Study 24515544 — intervention group
Group type: COMPARATOR
Intervention: Cystoscopic placebo injection and active oral medication
Number of subjects: 155
Study 22113254 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conservation therapy (BCT)
Number of subjects: 237
Study 22113254 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy (MRM)
Number of subjects: 237
Study 19823974 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping intervention (specific details not provided)
Number of subjects: 265
Study 19823974 — intervention group
Group type: COMPARATOR
Intervention: Baseline questionnaire (prior to being informed of genetic risk)
Number of subjects: 265
Study 18219956 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg per day)
Number of subjects: 108
Study 18219956 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapy)
Number of subjects: 108
Study 15742419 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin group (250 microg/h for 72 h)
Number of subjects: 60
Study 15742419 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin group
Number of subjects: 60
Study 15742419 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment group
Number of subjects: 60
Study 12057725 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian stimulation with FSH under pituitary suppression
Number of subjects: 88
Study 9854759 — intervention group
Group type: EXPERIMENTAL
Intervention: Control of early morning lumbar flexion
Number of subjects: 85
Study 9854759 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment of six ineffective exercises
Number of subjects: 85
Study 7833257 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-D (20 micrograms/kg)
Number of subjects: 43
Study 7833257 — intervention group
Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 43
Study 2142237 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg toremifene daily for 7 days
Number of subjects: 0
Study 2142237 — intervention group
Group type: EXPERIMENTAL
Intervention: 68 mg toremifene for 5 days
Number of subjects: 0
Study 2142237 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg tamoxifen for 5 days
Number of subjects: 0
Study 2142237 — intervention group
Group type: COMPARATOR
Intervention: Estrogen only (control group)
Number of subjects: 0
Study 426267 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 22
Study 426267 — intervention group
Group type: COMPARATOR
Intervention: Control group (19 patients)
Number of subjects: 22
Study 31999175 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based intervention (4 weekly calls + 5 biweekly calls)
Number of subjects: 33
Study 31999175 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based intervention
Number of subjects: 33
Study 31274183 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Sandostatin LAR monotherapy (40 mg)
Number of subjects: 68
Study 31274183 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Sandostatin LAR plus pegvisomant
Number of subjects: 68
Study 31274183 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Sandostatin LAR plus cabergoline
Number of subjects: 68
Study 31274183 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Sandostatin LAR monotherapy
Number of subjects: 68
Study 31274183 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Sandostatin LAR (all groups)
Number of subjects: 68
Study 31274183 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (including combinations)
Number of subjects: 68
Study 26975313 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Sports™ (WiiTM)
Number of subjects: 240
Study 26975313 — intervention group
Group type: COMPARATOR
Intervention: Arm exercises at home
Number of subjects: 240
Study 27067612 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial therapy protocol (21 minutes)
Number of subjects: 30
Study 24338522 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic medication switches
Number of subjects: 28
Study 24338522 — intervention group
Group type: COMPARATOR
Intervention: Confusion due to medication changes
Number of subjects: 28
Study 24338522 — intervention group
Group type: COMPARATOR
Intervention: No problems with medication changes
Number of subjects: 28
Study 23166441 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly
Number of subjects: 211
Study 23166441 — intervention group
Group type: COMPARATOR
Intervention: Exenatide once weekly and twice daily
Number of subjects: 211
Study 19220959 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced Glutathione (GSH) for 7‐14 days
Number of subjects: 40
Study 19220959 — intervention group
Group type: COMPARATOR
Intervention: Energy mixture (Control)
Number of subjects: 40
Study 17553207 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg intravenously every 3 months
Number of subjects: 215
Study 17553207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 15541406 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg vitamin E daily
Number of subjects: 486
Study 15541406 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg aspirin daily
Number of subjects: 486
Study 15541406 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vitamin E and low-dose aspirin
Number of subjects: 486
Study 15541406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 486
Study 11558863 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride 0.1% ophthalmic solution
Number of subjects: 111
Study 11558863 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride 0.05% ophthalmic solution
Number of subjects: 111
Study 11558863 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 111
Study 9156269 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid (TT) vaccine at 6, 8 and 14 months after BMT (early group, n = 23)
Number of subjects: 45
Study 9156269 — intervention group
Group type: COMPARATOR
Intervention: Tetanus toxoid (TT) vaccine at 18, 20 and 26 months after BMT (late group, n = 22)
Number of subjects: 45
Study 9156269 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid (TT) vaccine (both groups)
Number of subjects: 45
Study 9156269 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid (TT) vaccine (late group)
Number of subjects: 45
Study 8438741 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 100
Study 8438741 — intervention group
Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 100
Study 3028699 — intervention group
Group type: EXPERIMENTAL
Intervention: High fibre diet for 6 weeks
Number of subjects: 88
Study 3028699 — intervention group
Group type: COMPARATOR
Intervention: Low fibre diet throughout
Number of subjects: 88
Study 29024120 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg/d)
Number of subjects: 69
Study 29024120 — intervention group
Group type: COMPARATOR
Intervention: Denosumab (60 mg once/6 months)
Number of subjects: 69
Study 27146000 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 1.6104 CFU of WRSS1 vaccine
Number of subjects: 20
Study 27146000 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 20
Study 25608849 — intervention group
Group type: EXPERIMENTAL
Intervention: AG‐dieckol (1500 mg per day)
Number of subjects: 80
Study 25608849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23264069 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% lingual dextrose
Number of subjects: 0
Study 23264069 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 21040534 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening program for Q fever with immediate analysis of blood samples for IgG and IgM antibodies using a cut-off level of 1:32.
Number of subjects: 0
Study 21040534 — intervention group
Group type: COMPARATOR
Intervention: Control group with serum frozen for analysis after delivery.
Number of subjects: 0
Study 21040534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis comparing direct and indirect costs between intervention and control groups.
Number of subjects: 0
Study 18237574 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich diet (58% carbohydrate, 15% protein, 27% fat)
Number of subjects: 164
Study 18237574 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein diet (48% carbohydrate, 25% protein, 27% fat)
Number of subjects: 164
Study 18237574 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher unsaturated fat diet (48% carbohydrate, 15% protein, 37% fat)
Number of subjects: 164
Study 12803267 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined peri- and retrobulbar block
Number of subjects: 20
Study 12803267 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 20
Study 9583341 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete cognitive-behavioral therapy (CT)
Number of subjects: 137
Study 9583341 — intervention group
Group type: COMPARATOR
Intervention: Behavioral activation
Number of subjects: 137
Study 9583341 — intervention group
Group type: COMPARATOR
Intervention: Behavioral activation with automatic thought modification
Number of subjects: 137
Study 7624197 — intervention group
Group type: EXPERIMENTAL
Intervention: Colored environment 1
Number of subjects: 15
Study 7624197 — intervention group
Group type: EXPERIMENTAL
Intervention: Colored environment 2
Number of subjects: 15
Study 7624197 — intervention group
Group type: EXPERIMENTAL
Intervention: Colored environment 3
Number of subjects: 15
Study 2539762 — intervention group
Group type: COMPARATOR
Intervention: Quinapril 10 mg once daily
Number of subjects: 0
Study 2539762 — intervention group
Group type: COMPARATOR
Intervention: Quinapril 20 mg once daily
Number of subjects: 0
Study 2539762 — intervention group
Group type: COMPARATOR
Intervention: Quinapril 5 mg once daily
Number of subjects: 0
Study 2539762 — intervention group
Group type: COMPARATOR
Intervention: Quinapril administered once or twice daily
Number of subjects: 0
Study 2539762 — intervention group
Group type: COMPARATOR
Intervention: Quinapril in patients with refractory congestive heart failure
Number of subjects: 0
Study 335790 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (6 g daily) with unilateral ECT
Number of subjects: 0
Study 335790 — intervention group
Group type: COMPARATOR
Intervention: Placebo with unilateral ECT
Number of subjects: 0
Study 31044267 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine/Rituximab plus Ibrutinib (BR-I)
Number of subjects: 578
Study 31044267 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine/Rituximab plus Placebo (BR)
Number of subjects: 578
Study 26703983 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-specific nutritional formula enriched with arginine, zinc, and antioxidants
Number of subjects: 0
Study 26703983 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric-isonitrogenous support
Number of subjects: 0
Study 26703983 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-specific nutritional formula
Number of subjects: 0
Study 25925670 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture at Neiguan (PC6)
Number of subjects: 60
Study 25925670 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture at a non-acupoint
Number of subjects: 60
Study 25925670 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 60
Study 24068631 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/day for 6 weeks)
Number of subjects: 66
Study 24068631 — intervention group
Group type: EXPERIMENTAL
Intervention: ER-niacin (0.5 g/day for 3 weeks, then 1 g/day for 6 weeks)
Number of subjects: 66
Study 21378388 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin I (TnI) assessment at 24 hours (> 6.6 μg/l)
Number of subjects: 40
Study 21378388 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine kinase-MB isoform (CK-MB) assessment
Number of subjects: 40
Study 21378388 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the curve for TnI
Number of subjects: 40
Study 21378388 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the curve for CK-MB
Number of subjects: 40
Study 19151379 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 46
Study 19151379 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 46
Study 17947376 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS group
Number of subjects: 40
Study 15472216 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH treatment (6 mg/d) for 3 months
Number of subjects: 12
Study 15472216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11721171 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (anthracycline-based) for TCRBCL patients
Number of subjects: 10
Study 11721171 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (anthracycline-based) for DLBCL patients
Number of subjects: 10
Study 9720463 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved satisfaction with the physical workstation
Number of subjects: 577
Study 9720463 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved chair comfort
Number of subjects: 577
Study 9720463 — intervention group
Group type: EXPERIMENTAL
Intervention: Fewer housekeeping responsibilities
Number of subjects: 577
Study 9720463 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 577
Study 9720463 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pay range
Number of subjects: 577
Study 8172273 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranoprofen 0.1%
Number of subjects: 151
Study 8172273 — intervention group
Group type: COMPARATOR
Intervention: Fluorometholone 0.1%
Number of subjects: 151
Study 3145746 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg
Number of subjects: 0
Study 3145746 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg
Number of subjects: 0
Study 3145746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31375440 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5mcg or 15mcg of hemagglutinin (HA)/dose for children 6-35 months; 15mcg HA/dose for children 3-17 years, administered via intramuscular injection, two doses 21 days apart.
Number of subjects: 0
Study 31375440 — intervention group
Group type: EXPERIMENTAL
Intervention: H3N2v vaccine
Number of subjects: 0
Study 28124817 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly titration of IDegLira (based on mean of 2 pre-breakfast PG readings)
Number of subjects: 420
Study 28124817 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly titration of IDegLira (based on mean of 3 pre-breakfast PG readings)
Number of subjects: 420
Study 26106626 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 μg/d vitamin D3
Number of subjects: 68
Study 26106626 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 μg/d vitamin D3
Number of subjects: 68
Study 26106626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 23499427 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of depression and/or anxiety
Number of subjects: 200
Study 23499427 — intervention group
Group type: EXPERIMENTAL
Intervention: Complaints suggestive of underlying depressive and/or anxiety disorders
Number of subjects: 200
Study 21471758 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 12 mg
Number of subjects: 1048
Study 21471758 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 24 mg
Number of subjects: 1048
Study 21471758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1048
Study 19964412 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of the subthalamic nucleus (STN DBS) alone
Number of subjects: 45
Study 19964412 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 45
Study 19964412 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatments (STN DBS + medication)
Number of subjects: 45
Study 19964412 — intervention group
Group type: COMPARATOR
Intervention: No treatment (mof-sof)
Number of subjects: 45
Study 17242254 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation therapy (standardized 5-week course)
Number of subjects: 30
Study 15494583 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral arm training with rhythmic auditory cueing (BATRAC)
Number of subjects: 21
Study 15494583 — intervention group
Group type: COMPARATOR
Intervention: Standardized dose‐matched therapeutic exercises (DMTE)
Number of subjects: 21
Study 11448094 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (1 mg i.v.)
Number of subjects: 0
Study 11448094 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (100 mg p.o.)
Number of subjects: 0
Study 11448094 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg p.o.)
Number of subjects: 0
Study 11448094 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (2 mg p.o.)
Number of subjects: 0
Study 11448094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9506206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (Gamimune N)
Number of subjects: 62
Study 9506206 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 62
Study 7871106 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue‐non‐CFS group
Number of subjects: 55
Study 7871106 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CFS
Number of subjects: 55
Study 7871106 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 55